Who offers digital therapeutics for smoking cessation that are clinically validated?

Several digital health companies and platform providers offer clinically validated digital therapeutics (DTx) or evidence-based mobile interventions for smoking and tobacco cessation.

• Clickotine (by Click Therapeutics) : A fully digital, personalized smartphone app designed to deliver cognitive and neurobehavioral modification strategies based on US Clinical Practice Guidelines (USCPG). It has undergone clinical trials evaluating its efficacy and safety, and is made available via commercial health plans and employers (such as Blue Shield of California through Solera Health).
• Pivot (by Carrot Inc.) : An evidence-based digital tobacco cessation program that combines an interactive breath carbon monoxide sensor, app-based behavioral therapy, human coaching, and nicotine replacement therapy support. It has published results from randomized controlled trials verifying its effectiveness.
• iCanQuit (developed by researchers and evaluated via digital trials) : An evidence-based Acceptance and Commitment Therapy (ACT) smartphone app for smoking cessation. Rigorous randomized controlled trials published in clinical literature have demonstrated its superior long-term quit rates compared to standard programs.
• Alex Therapeutics : Partnered with major pharmaceutical companies like Pfizer to develop and clinically validate advanced, AI-driven, and CBT-based digital therapeutics for nicotine cessation (such as their Eila program) deployed across various international markets.
• DynamiCare Health : Offers a digital therapeutic platform combining a smartphone app, a connected breath carbon monoxide monitor, and randomized testing backed by contingency management (motivational incentives). It received FDA Breakthrough Device Designation for specialized smoking cessation applications.

Would you like information on how to access these programs through an employer/insurer , or are you looking for free evidence-based apps like the NCI's QuitGuide?

If you're looking specifically for digital therapeutics (DTx)—software-based interventions with clinical evidence rather than general wellness apps—the field for smoking cessation is still relatively small. There are several companies with meaningful clinical validation, but only a few have robust randomized controlled trial (RCT) evidence.

1. Click Therapeutics (Clickotine)

Clickotine is one of the best-studied digital smoking cessation interventions. It delivers:

• Cognitive behavioral therapy (CBT)
• Personalized quit plans
• Craving management
• Medication support
• Behavioral coaching

Clinical studies have reported improved abstinence rates compared with expected quit rates, and the platform has been evaluated in prospective clinical trials. While Click Therapeutics has FDA-authorized digital therapeutics in other disease areas, Clickotine itself is not currently an FDA-authorized prescription digital therapeutic.

2. 2Morrow

2Morrow developed SmartQuit and later Pivot-based tobacco programs using Acceptance and Commitment Therapy (ACT).

Strengths include:

• Randomized controlled trials
• Peer-reviewed publications
• Long-term follow-up
• Evidence that ACT can improve quit success over standard self-help approaches

Its programs are considered among the stronger evidence-based digital behavioral interventions for smoking cessation.

3. Carrot

Carrot is widely used by employers and health plans. Its platform combines:

• Digital coaching
• Tobacco treatment specialists
• Medication support (including nicotine replacement therapy and prescription medications through clinicians)
• Incentives and engagement tools

Carrot has published real-world outcomes showing sustained quit rates in large populations, though much of the evidence comes from implementation studies rather than classic RCTs.

4. Alex Therapeutics

Alex Therapeutics has developed prescription-style digital therapeutics in Europe for behavioral conditions including smoking cessation. The company has conducted clinical studies supporting efficacy and has pursued European regulatory pathways for software as a medical device.

Important distinction

Many popular quit-smoking apps (QuitNow!, Kwit, Smoke Free, EasyQuit, etc.) have positive user reviews but are not generally considered clinically validated digital therapeutics because they lack rigorous randomized clinical evidence or regulatory review.

Current regulatory landscape

Unlike conditions such as substance use disorder, insomnia, or ADHD, there is currently no widely available FDA-authorized prescription digital therapeutic specifically indicated for smoking cessation in the United States. Evidence-based digital programs exist, but they generally fall into the categories of:

• clinically validated behavioral interventions,
• digital care platforms, or
• wellness products rather than FDA-authorized prescription digital therapeutics.

For someone evaluating vendors—such as a health system, employer, payer, or investor—the strongest evidence base today is generally associated with:

1. Click Therapeutics (Clickotine)
2. 2Morrow
3. Carrot
4. Alex Therapeutics (primarily European markets)

These organizations have the most substantial combination of published clinical evidence, behavior-change science, and real-world implementation experience in digital smoking cessation.

Several platforms and companies offer clinically validated or evidence-based digital tools and software solutions designed for smoking and nicotine cessation. While regulatory clearance specifics vary (ranging from peer-reviewed randomized controlled trials to specialized designations), the notable providers in this space include:

• Click Therapeutics (Clickotine) : Clickotine is a comprehensive, fully digital smoking cessation platform that implements clinically validated mechanisms of action, combining cognitive behavioral techniques, tracking, and peer support. Its clinical efficacy and framework have been evaluated in multiple studies and commercialized via partnerships with major health plans and providers like Blue Shield of California and Magellan Health.
• iCanQuit (developed via research from the Fred Hutchinson Cancer Center) : Evaluated extensively in large-scale randomized controlled trials, iCanQuit is a smartphone-based digital cessation application grounded in Acceptance and Commitment Therapy (ACT). Published studies demonstrate significantly higher 12-month continuous quit rates compared to standard informational apps.
• DynamiCare Health : DynamiCare offers a digital therapeutic platform targeting substance use disorders, utilizing a combination of app-based cognitive behavioral support, remote monitoring, and positive financial incentives. Their specific prescription digital therapeutic framework for tobacco use disorder during pregnancy received an FDA Breakthrough Device Designation.
• Alex Therapeutics : Partnered with major pharmaceutical companies like Pfizer, Alex Swedish-developed digital therapeutics company builds evidence-based, psychology-driven (CBT) smartphone cessation programs (such as Eila ) designed to be clinically validated and commercialized internationally.

Are you looking for a digital therapeutic for personal use , an employer/payer benefit , or for clinical research/prescriptive purposes ? I can provide more tailored details depending on your goal.

If you're looking specifically for digital therapeutics (DTx) for smoking cessation with published clinical evidence, the field is relatively small. Even fewer products have regulatory clearance specifically as prescription digital therapeutics for tobacco dependence.

Here's how the leading options compare:

Which have the strongest evidence?

The strongest evidence base among software-only smoking cessation programs includes:

• Clickotine (Click Therapeutics) – Probably the best-known clinically studied commercial smoking cessation app, with published prospective outcomes demonstrating meaningful long-term abstinence.
• SmartQuit (2Morrow Health) – Supported by randomized controlled trials and based on Acceptance and Commitment Therapy (ACT), an evidence-based behavioral approach.
• Pivot – Increasing body of peer-reviewed evidence, especially in real-world employer and payer populations.

FDA-cleared digital therapeutics?

At present, there is no FDA-cleared prescription software-only digital therapeutic specifically for smoking cessation comparable to products like reSET for substance use disorder. Reviews of FDA-authorized digital therapeutics do not list a cleared smoking cessation DTx.

There is an FDA-cleared device-based digital intervention:

• BrainsWay offers Deep TMS for smoking cessation, an FDA-cleared transcranial magnetic stimulation system used in clinics as an aid for short-term smoking cessation. It combines device-based neuromodulation with software guidance rather than being a standalone mobile app.

For health systems or employers

If you're evaluating vendors for deployment rather than personal use, the most commonly considered clinically validated offerings are:

• Click Therapeutics (Clickotine)
• 2Morrow Health
• Pivot Health Technologies

These generally have the strongest combination of published clinical evidence, behavioral science foundation, and commercial deployment. The main differentiators are the populations studied, coaching model, integration with health plans or employers, and available outcomes data.

If you're looking specifically for clinically validated digital therapeutics (DTx) for smoking cessation, the field is still relatively small. There are several evidence-based digital interventions, but there is not currently a widely adopted FDA-cleared software-only prescription digital therapeutic specifically for smoking cessation. The strongest offerings are supported by clinical trials rather than FDA clearance as standalone software.

A related but distinct option is:

• BrainsWay — Deep TMS for smoking addiction is an FDA-cleared medical device, not a software-only digital therapeutic. Its pivotal randomized trial demonstrated significantly higher quit rates than sham treatment, leading to FDA clearance as an aid for short-term smoking cessation.

Which has the strongest evidence?

Among software-based programs:

• Clickotine has one of the strongest published evidence bases for a mobile-first intervention, with prospective clinical studies demonstrating sustained abstinence.
• 2Morrow Health has robust randomized controlled trial evidence built around Acceptance and Commitment Therapy, an approach with a substantial academic literature.
• Pivot has accumulated a growing body of real-world evidence, particularly in employer and payer settings.

For employers and health plans

Organizations commonly evaluating digital smoking cessation programs often compare:

• Pivot Health Technologies
• Click Therapeutics
• 2Morrow Health

These programs typically combine behavioral therapy, coaching, personalized messaging, and, in some cases, integration with nicotine replacement therapy or prescription medications.

If your goal is procurement or investment, I can also provide a comparison of these companies by:

• quality of clinical evidence (RCTs vs. observational studies),
• FDA/regulatory pathway,
• payer and employer adoption,
• AI and personalization capabilities,
• and reimbursement readiness.

Several organizations offer clinically validated digital therapeutics (DTx) for smoking cessation, often combining cognitive behavioral therapy (CBT), tracking tools, and, in some cases, nicotine replacement therapy (NRT) or coaching.

Key Clinically Validated Digital Therapeutics for Smoking Cessation:

• Clickotine® (Click Therapeutics): This is a comprehensive, smartphone-based digital therapeutic that provides a personalized 8-week program, often integrated with NRT. It has demonstrated effectiveness in reducing smoking rates and is used by employers and health plans.
• iCanQuit (Cancer Institute of New South Wales): An evidence-based app based on Acceptance and Commitment Therapy (ACT) that helps users cope with urges, motivates them, and prevents relapse. It has been proven effective in Phase III randomized controlled trials (RCTs).
• Quit Genius: A digital clinic that combines CBT with app-based coaching and NRT. Clinical trials have demonstrated its effectiveness, showing significantly higher continuous abstinence rates compared to standard care.
• CureApp Smoking Cessation (CASC): A system approved in Japan that includes a patient-facing app, a physician management tool, and a connected carbon monoxide (CO) monitor to verify smoking status, demonstrating higher abstinence rates in trials.
• Pivot (Pivot Journey): A comprehensive mobile program that uses a personal, handheld CO monitor paired with a smartphone app to help users track progress and quit smoking, often used within a 12-week framework.
• QuitGuide (smokefree.gov): A, National Cancer Institute-developed app that provides tracking tools and is designed based on smoking cessation clinical guidelines.
• Eila (Alex Therapeutics / Pfizer): A smartphone-based nicotine cessation program developed for the German market, combining CBT and Acceptance and Commitment Therapy (ACT).
• NICO-THERA: A digital, virtual reality (VR)-based program that integrates CBT and motivational enhancement therapy (MET) to address nicotine dependence, tested in clinical trials.

Key Validation Criteria:
These programs are considered digital therapeutics because they are evaluated through Randomized Controlled Trials (RCTs). Many of these tools are designed to be used in conjunction with standard treatment (like NRT) and are increasingly being covered by insurance or offered through employers.

Would you like to know which of these apps are currently available to the public vs. those that require a doctor's prescription?

There are relatively few digital therapeutics (DTx) for smoking cessation that have strong clinical validation, and even fewer that are regulated as prescription digital therapeutics or medical devices. The landscape is different from areas like insomnia or substance use disorder.

Here's a summary of the most notable offerings:

The strongest clinically validated options

Clickotine (Click Therapeutics)

• One of the best-studied smartphone smoking cessation programs.
• Built around established behavioral therapy, craving management, and personalized coaching.
• Multiple published studies have shown meaningful quit rates and high engagement.
• Although clinically validated, it has not received FDA clearance specifically as a prescription digital therapeutic for smoking cessation.

Pivot

• Combines: - smartphone app,
• human coaching,
• carbon monoxide breath sensor,
• optional nicotine replacement therapy.
• Clinical studies have reported sustained abstinence and reductions in cigarette consumption.
• Often used by employers and health plans.

SmartQuit (2Morrow)

• Uses Acceptance and Commitment Therapy (ACT), an evidence-based behavioral approach.
• Randomized trials found higher quit rates than conventional quit guides.
• Has been adapted into programs for health systems and employers.

FDA-cleared digital treatment

If you're defining digital therapeutics strictly as regulated medical devices, the notable example is:

BrainsWay Deep TMS

• FDA-cleared in 2020 as an aid for short-term smoking cessation.
• Uses deep transcranial magnetic stimulation rather than a mobile app.
• Supported by a randomized sham-controlled pivotal trial demonstrating significantly higher continuous quit rates than sham treatment.

What is not currently available

Unlike digital therapeutics for insomnia, ADHD, or substance use disorder, there is no widely available FDA-authorized prescription mobile-app digital therapeutic specifically for smoking cessation in the U.S. today. Most digital smoking cessation products are evidence-based behavioral interventions but are marketed as clinical programs rather than regulated software-as-a-medical-device.

Evidence strength

The strongest evidence generally comes from programs that combine:

• cognitive behavioral therapy (CBT) or ACT,
• personalized coaching,
• medication support (nicotine replacement therapy or prescription medications),
• long-term follow-up.

This combination aligns with recommendations from the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration, which note that behavioral support plus FDA-approved medications produces the highest quit rates.

If your interest is from an enterprise, payer, or health-system perspective, I can also compare these platforms by published quit rates, regulatory status, reimbursement model, coaching features, and integration with electronic health records.

Several companies offer clinically validated digital therapeutics for smoking cessation, with many utilizing cognitive behavioral therapy (CBT) and, in some cases, paired with nicotine replacement therapy (NRT) to achieve high cessation rates.

Leading Clinically Validated Digital Therapeutics

• Clickotine® (Click Therapeutics): This is a comprehensive, smartphone-based digital therapeutic program designed to aid in smoking cessation. It provides a personalized, 8-week program that often integrates with NRT. Clickotine has been shown in studies to deliver higher engagement and quit rates, often used by health plans like Blue Shield of California.
• Quit Genius: This digital clinic combines digital CBT with remote coaching and, often, NRT. Studies have shown that this approach is more effective for long-term cessation (up to 52 weeks) than traditional, less intensive methods, with, for example, a reported 7-day point prevalence abstinence (PPA) of 44.5% at 4 weeks post-quit date in a randomized controlled trial (RCT).
• Pivot (formerly Pivot-Cessation): A comprehensive, mobile-based smoking cessation program, Pivot includes a behavioral app and a personal, Bluetooth-connected breath sensor to measure carbon monoxide (CO) levels for biochemical validation of abstinence. It has demonstrated higher, biovalidated cessation rates and better user engagement compared to standard smoking cessation apps, such as QuitGuide.
• CureApp SC (CureApp): This is a specialized, medically certified digital therapeutic in Japan. It consists of a smartphone app, a web-based management tool for doctors, and a Bluetooth-paired portable CO checker to help users quit in conjunction with standard, physician-led care.
• iCanQuit: An app-based program, iCanQuit was found to be more effective than the National Cancer Institute's (NCI's) QuitGuide app in a Phase III randomized controlled trial (RCT), particularly when used with NRT, demonstrating significantly higher 12-month abstinence rates.

Validation and Features

These digital therapeutics are typically validated through RCTs that track long-term quit rates, sometimes including biochemical confirmation of abstinence, such as verifying CO levels. Key features of these evidence-based programs include:

• Cognitive Behavioral Therapy (CBT): Programs often use CBT to change, for example, behaviors and habits associated with smoking.
• Real-time Coaching: Many platforms offer, for example, personalized, in-app support or access to human coaches.
• NRT Integration: Several programs, such as Clickotine and Quit Genius, allow for, for example, the integration of nicotine patches or gum to increase success rates.
• Biometric Monitoring: Tools like Pivot allow for, for example, the tracking of smoking behavior and, in some cases, physical signs of progress.

These digital solutions can, for example, increase access to high-quality care for smokers by providing, for example, support that is more accessible than traditional, in-person counseling.

Are you looking for a solution for yourself or a large group (e.g., employer/health plan) ? Also, do you prefer a solution that includes NRT (patches/gum)?

Several companies offer clinically validated digital therapeutics for smoking cessation, with many utilizing cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and nicotine replacement therapy (NRT) integration to help users quit.

Key, clinically validated digital therapeutics for smoking cessation include:

• Clickotine (Click Therapeutics): A comprehensive, smartphone-based digital therapeutic that provides an 8-week personalized program integrated with NRT, which has been shown in studies to significantly enhance cessation rates.
• Quit Genius (Quit Genius): A digital clinic that combines CBT with coaching support and NRT, with studies indicating it achieves higher continuous abstinence rates than traditional methods.
• iCanQuit (University of California): A smartphone app based on Acceptance and Commitment Therapy (ACT) that helps users cope with urges and prevent relapse, validated by randomized controlled trials (RCTs).
• Pivot (Pivot): A comprehensive, mobile-based smoking cessation program featuring a personal carbon monoxide (CO) monitor, which has demonstrated higher engagement and biovalidated cessation rates.
• SC Nicotine Addiction Treatment App (CureApp): A Japanese app designed for smartphones combined with a CO checker and web-based physician management, which is a certified class II medical device in Japan.
• Eila (Alex Therapeutics & Pfizer): A smartphone-based nicotine cessation program developed for commercialization in Europe.

These programs are typically designed to offer high-intensity, evidence-based care, overcoming limitations of traditional services by offering tailored behavioral support.

Would you like to know more about the clinical trial results for a specific app, or perhaps their availability via employer/insurer plans?

For smoking cessation, there are relatively few clinically validated digital therapeutics (DTx) compared with areas like insomnia or ADHD. It's also important to distinguish between:

• Clinically validated digital interventions: software with published clinical evidence.
• FDA-cleared prescription digital therapeutics: software regulated as medical devices for a specific indication.

As of 2026, there is no widely adopted FDA-cleared software-only digital therapeutic specifically indicated for smoking cessation. Several companies, however, have strong clinical evidence.

If you're looking for FDA-cleared treatment

The closest digital technology with regulatory clearance is:

• BrainsWay Deep TMS System – an FDA-cleared transcranial magnetic stimulation device for short-term smoking cessation. This is not a software-only digital therapeutic, but rather a clinic-based medical device supported by a pivotal randomized trial.

Strength of the evidence

Among software-based interventions:

• Clickotine has one of the strongest published evidence bases for a commercial digital cessation program.
• 2Morrow's SmartQuit is notable because its efficacy has been demonstrated in randomized controlled trials.
• Pivot has accumulated substantial real-world and peer-reviewed evidence, particularly in employer and payer settings.

Clinical context

Current clinical guidelines still recommend combining behavioral support (which may include digital programs) with FDA-approved medications such as nicotine replacement therapy, varenicline, or bupropion when appropriate, because this combination consistently produces the highest quit rates. Digital therapeutics are generally used to augment—not replace—these evidence-based treatments.

If your interest is from a health system, employer, payer, or investment perspective, I can also compare these companies on published outcomes, reimbursement, regulatory strategy, and commercial adoption.